[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Deling Li\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100606586",false,"NCT07177482","ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients","Inclusion criteria:\n\n* must be able to provide a written informed consent\n* radiologically presumed and\u002For histologically confirmed craniopharyngioma scheduled for resection\n* adequate clinical condition (Karnofsky performance status ≥70)\n\nExclusion criteria:\n\n* concomitant major central nervous system disorders\n* severe hepatic or renal dysfunction\n* history of severe allergy or hypersensitivity to intravenous radiographic contrast agents\n* claustrophobia precluding PET\u002FCT or MRI examinations\n* pregnancy or breastfeeding","ALL","14 Years","80 Years",{"count":18,"type":19},20,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study aims to investigate 68Ga-MY6349, an immune-PET tracer targeting trophoblast cell surface antigen 2 (Trop2), for the noninvasive diagnosis of craniopharyngioma in vivo.",[25],"Craniopharyngioma",[27,28],"Positron-Emission Tomography","Diagnosis","RECRUITING","2025-09-10",{"date":32,"type":33},"2025-09-17","ACTUAL",{"date":35,"type":33},"2025-07-04",{"date":37,"type":19},"2026-12-31",{"name":39,"class":40},"Deling Li","OTHER",""]